Menu

Table of Contents:

Read online

C. Graux MD, PhD

Service Hématologie, CHU UCL Namur, Site Godinne, Yvoir, Belgium
CHU Mont-Godinne, Godinne, Belgium
Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Haemostasis Centre (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.

Articles

Acute graft-versus-host disease: diagnosis, pathophysiology and prevention

BJH - volume 11, issue 4, june 2020

B. Vandenhove PhD student, L. Canti PhD student, H. Schoemans MD, PhD, Y. Beguin MD, PhD, F. Baron MD, PhD, E. Willems MD, PhD, C. Graux MD, PhD, T. Kerre MD, PhD, S. Servais MD, PhD

SUMMARY

Acute graft-versus-host disease (aGVHD) remains a severe complication after allogeneic stem cell transplantation (alloHCT). It is a disregulated immune process, during which the immune cells of the donor attack the healthy tissues in the immunocompromised host. Over the past two decades, progress in understanding its pathophysiology have helped redefine aGVHD reactions and clinical presentations. Typically, the disease presents with serious inflammatory lesions mainly in the skin, gut and liver. Its severity is assessed by gathering clinical signs and dysfunctions of each organ. Despite standard prophylaxis regimens, aGVHD still occurs in approximately 30–60% of transplanted patients and remains a major cause of transplant-related morbidity and mortality. Hence, there is an urgent need for optimising preventive strategies. In this review, we give insights on how to make an accurate diagnosis and scoring assessment of aGVHD, propose a short overview of the current knowledge about its immunobiology and discuss the current and developing strategies for prevention.

(BELG J HEMATOL 2020;11(4):159–173)

Read more

P.46 Hepatitis E management in allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients: a case report

BJH - volume 11, issue Abstract Book BHS, february 2020

G. Crochet , M. Bourgeois , E. Collinge , H. Vellemans , M. André MD, A. Sonet MD, C. Graux MD, PhD

Read more

O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation – a multicenter prospective study

BJH - volume 11, issue Abstract Book BHS, february 2020

S. Servais MD, PhD, F. Baron MD, PhD, C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, PhD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, prof. dr. P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD

Read more

O1 Prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation in high risk acute leukemia and myelodysplastic syndromes: a single-center retrospective study.

BJH - 2018, issue Abstract Book BHS, february 2018

E. Collinge , C. Graux MD, PhD, M. André MD, H. Labussière-Wallet , M. Michallet , G. Salles

Read more

O2 In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions

BJH - 2018, issue Abstract Book BHS, february 2018

H. Haguet , J. Douxfils PhD, PharmD, C. Chatelain MD, C. Graux MD, PhD, F. Mullier PhD, PharmD, J-M. Dogné PhD, PharmD

Read more

PP06 Hereditary predisposition syndromes to malignant hemopathies (HPSMH)

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dupriez , A. Ferrant , M-C. Vekemans MD, B. Brichard , L. Michaux MD, PhD, T. Connerotte , E. Van den Neste MD, PhD, C. Vermylen , L. Knoops MD, PhD, C. Graux MD, PhD, F. Duhoux , C. Lambert MD, X. Poiré MD, PhD, H.A. Poirel MD, PhD

Read more

Blinatumomab: beyond clinical trials

BJH - volume 8, issue 3, june 2017

C. Graux MD, PhD

SUMMARY

Immunotherapy is an alternative treatment modality for poor conditions associated with chemoresistance like refractory/relapsing primary B-precursor acute lymphoblastic leukaemia or minimal residual disease persistence. The immunotherapeutic effect of allogeneic stem cell transplantation is largely exploited in this context but graft-versus-host disease remains a major concern. Recently, improvements have been made in selectively engaging the immune system against the persistent disease. Blinatumomab is a dual binding antibody construct that redirects any T lymphocytes against B-precursor acute lymphoblastic leukaemia blasts. It shows a very good activity in monotherapy in those poor risk conditions and is associated with a low toxicity profile suggesting this use earlier and in combination in the therapeutic course of B-precursor acute lymphoblastic leukaemia patients. In this article, after a short overview of immunotherapeutic advances in B-precursor acute lymphoblastic leukaemia, the results of the main trials conducted with blinatumomab are discussed and put in perspective.

(BELG J HEMATOL 2017;8(3):107–12)

Read more
X